Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Low-molecular-weight heparins

J N Huang1, A Shimamura

  • 1Division of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

Hematology/Oncology Clinics of North America
|January 29, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Type 2 inflammation promotes distinct metabolic profiles in chronic rhinosinusitis with nasal polyps.

Rhinology·2026
Same author

[Forcasting the prevalence of myopia among students aged 6-18 years in China from 2021 to 2030].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2021
Same author

Dermatological manifestations of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis (POIKTMP): a case series of 28 patients.

The British journal of dermatology·2019
Same author

[Progress on the lifeomics studies of chronic obstr uctive pulmonary disease].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2019
Same author

[Rituximab for primary focal segmental glomerulosclerosis].

Zhonghua nei ke za zhi·2017
Same author

[Research advances in diabetic retinopathy telescreening systems].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2016
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Low-molecular-weight heparins (LMWH) offer a significant advance in anticoagulant therapy. These agents provide predictable dosing and eliminate routine monitoring, simplifying patient care compared to unfractionated heparin (UFH) and warfarin.

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Low-molecular-weight heparins (LMWH) represent a novel class of parenteral anticoagulants.
  • Their development marks a significant progression in anticoagulant therapy since unfractionated heparin (UFH) and warfarin.

Purpose of the Study:

  • To review recent clinical trials on LMWH.
  • To compare the efficacy and administration of LMWH against UFH and coumadin.

Main Methods:

  • Literature review of recent clinical trials.
  • Comparative analysis of anticoagulant studies.

Main Results:

  • LMWH exhibit predictable pharmacokinetics and improved bioavailability.
  • Longer plasma half-life allows for simplified once- or twice-daily dosing.

Related Experiment Videos

  • Routine laboratory monitoring is not required for LMWH.

    • Conclusions:

    • LMWH offer a more convenient and potentially safer alternative to traditional anticoagulants.
    • Simplified administration of LMWH is poised to transform clinical anticoagulation practices.
    • Further research supports LMWH as a key therapeutic option.